News: Simtuzumab

We provide the latest news and info on Simtuzumab


Pulmonary Fibrosis News

Simtuzumab (GS-6624)
Pulmonary Fibrosis News
Simtuzumab, also known as GS-6624 is a pipeline drug being developed by Gilead Sciences for the treatment of Idiopathic Pulmonary Fibrosis and related conditions like Cirrhosis developed from Non-Alcoholic Steato Hepatitis (NASH).

Published on Tuesday 28th of July 2015 01:13:51 AM Read more...


Idiopathic Pulmonary Fibrosis: KOL Insight
PR Newswire (press release)
NEW YORK, July 21, 2015 /PRNewswire/ -- Roche's Esbriet, (pirfenidone) and Boehringer Ingelheim's Ofev (nintedanib) are the only approved therapies for Idiopathic Pulmonary Fibrosis (IPF). Will either be able to establish themselves as first choice ...

and more »

Published on Tuesday 28th of July 2015 01:13:51 AM Read more...


Bidness ETC

Gilead's simtuzumab fails pancreatic cancer trial
PMLiVE
Gilead Sciences has suffered a setback after its cancer candidate simtuzumab failed to achieve a survival benefit in a pancreatic cancer trial. The phase II study of simtuzumab (GS-6624) - an inhibitor of lysyl oxidase-like-2 (LOXL2) - showed that the ...
Gilead Down on Weak Simtuzumab Data and Sovaldi NewsZacks.com
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously ...MarketWatch
Gilead Releases Phase 2 Pancreatic Cancer DataDrug Discovery & Development
Wall Street Journal -FierceBiotech
all 45 news articles »

Published on Tuesday 28th of July 2015 01:13:51 AM Read more...


Drug Discovery & Development

What Does Orphan Drug Approval For Gilead Sciences, Inc. (GILD)'s Simtuzumab Mean?
InvestCorrectly
Gilead Sciences, Inc. (NASDAQ:GILD)'s monoclonal antibody Simtuzumab recently obtained orphan drug status as a treatment for a rare liver-related disorder – primary sclerosing cholangitis. The designation may provide Gilead increased patent protection ...
Gilead Sciences: A 'Logical' Deal That 'Fits Well'Barron's
Gilead Sciences Inc To Acquire Phenex's Liver-Disease ProgramBidness ETC
Update: Gilead Acquires Another Drug Candidate (GILD)Seeking Alpha
Benzinga
all 107 news articles »

Published on Tuesday 28th of July 2015 01:13:51 AM Read more...


Smarter Analyst

Gilead Sciences, Inc. (GILD): Owning Ahead Of Earnings To Position For ...
Smarter Analyst
Herein we discuss several important drivers for Gilead Sciences, Inc. (NASDAQ:GILD) shares going into 2Q15/2016. HCV remains important and the growth is not over, we discuss where we see upside to estimates from such as Italy and EM. Moving beyond ...

and more »

Published on Tuesday 28th of July 2015 01:13:51 AM Read more...


GuruFocus.com (registration)

It's Not Too Late To Buy Gilead Sciences
GuruFocus.com (registration)
Notably, Gilead Sciences is developing a (Monoclonal Antibody) Simtuzumab, now in Phase 2, for the treatment of patients with indications of NASH, and Primary Sclerosing Cholangitis. Gilead Sciences looks set to stamp its authority in the development ...

and more »

Published on Tuesday 28th of July 2015 01:13:51 AM Read more...


The 2015 Calendar Of NASH Trial Catalysts IV: GENFIT And Gilead
Seeking Alpha
Gilead expects 48th-week interim readouts in H2 2015 of two Phase 2b RCTs of simtuzumab (GS-6624). Simtuzumab is an inhibitory monoclonal antibody against the L2 type of lysyl oxidase (LOX), an important enzyme family that stabilizes the extracellular ...

and more »

Published on Tuesday 28th of July 2015 01:13:51 AM Read more...

Our Services

Do not forget to check the lastest products and auctions related to Simtuzumab as well as our free videos and podcasts.

best Simtuzumab products current Simtuzumab auctions current Simtuzumab videos listen to Simtuzumab podcasts